If de novo CML-BP presents as an acute myeloid neoplasm, an assignment based on cytogenetics or molecular genetics by detection of the t(9;22) translocation or the BCR::ABL1 fusion transcript becomes obvious, because acute myeloid leukemia (AML) with BCR::ABL1 is a rare entity. This evidence concerns the gene ABL1 and acute myeloid leukemia.